- Home
- PGY vs AUPH Comparison
PGY vs AUPH Comparison
Compare PGY & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PGY | AUPH |
|---|---|---|
| Founded | 2016 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | PGY | AUPH |
|---|---|---|
| Price | $21.85 | $16.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $39.86 | $17.25 |
| AVG Volume (30 Days) | ★ 2.5M | 1.3M |
| Earning Date | 02-12-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | ★ $1,245,946,000.00 | $265,808,000.00 |
| Revenue This Year | $28.75 | $21.76 |
| Revenue Next Year | $17.23 | $16.45 |
| P/E Ratio | ★ N/A | $29.59 |
| Revenue Growth | ★ 28.33 | 20.62 |
| 52 Week Low | $8.27 | $6.55 |
| 52 Week High | $44.99 | $16.54 |
Technical Indicators
Market Signals| Indicator | PGY | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 40.60 | 63.13 |
| Support Level | $22.72 | $16.00 |
| Resistance Level | $24.06 | $16.54 |
| Average True Range (ATR) | 1.31 | 0.41 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 16.63 | 80.58 |
Price Performance
Historical ComparisonAbout PGY Pagaya Technologies Ltd.
Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.